| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) investing activities | 195,975 | -5,634 |
| Repurchase of common stock | 342,372 | 303,489 |
| Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement | 17,683 | 1,202 |
| Net cash (used in) provided by financing activities | -324,689 | -302,287 |
| Net increase in cash and cash equivalents | 303,815 | -53,989 |
| Cash and cash equivalents at beginning of period | 115,850 | - |
| Cash and cash equivalents at end of period | 419,665 | - |
HALOZYME THERAPEUTICS, INC. (HALO)
HALOZYME THERAPEUTICS, INC. (HALO)